This comprehensive volume offers detailed, step-by-step protocols for isolating, characterizing, and analyzing ocular cells and tissues—particularly from the anterior segment, where ocular hypertension originates. Covering molecular biology, pharmacology, and histological approaches, the book bridges laboratory research and clinical application through reproducible and translationally relevant methodologies.
Spanning eight thematic sections, the book discusses ocular anatomy, receptor localization, cell-based assays, in vitro and in vivo models, drug formulation, and cutting-edge tools such as gene editing, single-cell RNA sequencing, and stem cell–based approaches. Designed to support scientists in ophthalmic drug discovery and translational research, it also integrates novel techniques such as CRISPR, metabolomics, and exosome analysis.
“Drs. Sharif and Ohia have compiled an outstanding volume that brings together a comprehensive collection of protocols for studying disease mechanisms and identifying or validating drug targets in glaucoma. The book serves as a valuable reference for researchers working in the areas of ocular hypertension and glaucoma..”
W. Daniel Stamer, Ph.D., FARVO, Professor of Ophthalmology and Biomedical Engineering, Duke University, USA
Learn more about this book here: http://bit.ly/48EwEBl
For media inquiries, review copies, or interviews, please contact Bentham Science Publishers.
Dr. Najam A. Sharif
Dr. Najam (Naj) Sharif, PhD, DSc (University of Southampton, UK), is an accomplished pharmaceutical scientist with over three decades of experience in neuroscience and ophthalmology. He played a pivotal role in the development and FDA approval of several major ocular therapeutics including Patanol, Emadine, Travatan, and Simbrinza. A Fellow of ARVO, AOPT, and the British Pharmacological Society, Dr. Sharif is the recipient of numerous honors such as the Roger Vogel Award, Sir James Black Award, and the Ernst H. Barany Prize. Currently serving as Vice President at Nanoscope Therapeutics, he leads R&D in optogenetic gene therapy for retinal diseases.
Dr. Sunny E. Ohia
Dr. Sunny E. Ohia, PhD, is a Professor of Pharmacology at Texas Southern University’s College of Pharmacy and Health Sciences, USA. With more than 40 years of academic and research experience across North America, Dr. Ohia directs the Ophthalmic Pharmacology Research Laboratory and has made significant contributions to understanding ocular pharmacology and drug mechanisms. A Fellow of the Association for Research in Vision and Ophthalmology (ARVO), he has authored over 250 scientific publications and holds eight patents worldwide.